Juno Bio raises $3.8M to scale precision vaginal microbiome testing
What's the deal? Juno BioDealroom has a profile for this one. Try Dealroom → has raised $3.8 million in an early-stage round from Ada VenturesDealroom has a profile for this one. Try Dealroom →, ArtesianDealroom has a profile for this one. Try Dealroom →, Entrepreneur FirstDealroom has a profile for this one. Try Dealroom →, and Illumina Accelerator to scale precision vaginal microbiome testing. The Oakland-based startup uses next-generation sequencing to diagnose conditions that standard tests often miss.
Why now? The round coincides with Juno Bio opening its first CLIA-certified sequencing lab in Oakland, California, dedicated entirely to women's health. The facility processes tests the company previously outsourced.
What's the endgame? Where a standard clinical test checks for a handful of pathogens, Juno Bio's platform screens for around 10,000 bacteria and fungi alongside four common STIs. The goal is to help clinicians tell apart conditions that look identical under a microscope, including bacterial vaginosis, yeast infections, and aerobic vaginitis.
Co-founded in 2018 by Hana JanebdarDealroom has a profile for this one. Try Dealroom → and Dr. Leighton TurnerDealroom has a profile for this one. Try Dealroom →, Juno Bio has sold more than 20,000 kits and built one of the largest vaginal microbiome datasets in the field. Its new test is the first designed to inform clinical decisions rather than consumer curiosity.
According to the company's clinical data, 67.5% of patients who later used its platform had been misdiagnosed, underdiagnosed, or overdiagnosed beforehand, and only 13% had been successfully treated. Roughly half had co-infections that conventional testing missed entirely.
What could go wrong? Juno Bio faces competition. New York-based EvvyDealroom has a profile for this one. Try Dealroom → has raised $19 million to date, including a $14 million Series A led by Left Lane CapitalDealroom has a profile for this one. Try Dealroom →, and also uses metagenomic sequencing. DayeDealroom has a profile for this one. Try Dealroom → is pushing into diagnostics through a tampon-based collection method.
Juno Bio positions itself differently. Rather than a direct-to-consumer wellness brand, it aims to be clinical infrastructure — a data layer that other providers and pharmaceutical researchers can build on.
That distinction underpins the funding thesis. "What they've built at this stage, with this level of capital efficiency, is exceptional," says Check WarnerDealroom has a profile for this one. Try Dealroom →, co-founding partner at Ada Ventures.
Janebdar frames the round as a scaling moment. "This next chapter is about scaling that work, expanding access to more actionable care, and continuing to close the gender health gap," she says.
The signal: The $3.8 million round is modest — landing in the bottom fifth of comparable raises — but the bet is bigger: that underinvestment in women's health is a correctable market failure, and that clinical-grade diagnostics can turn an overlooked category into infrastructure others build on.
Read more: Tech Funding News
